MC 1288

Drug Profile

MC 1288

Alternative Names: 20-Epi-1,25-dihydroxyvitamin-D3

Latest Information Update: 25 Jul 2001

Price : $50

At a glance

  • Originator LEO Pharma
  • Developer LEO Pharma; Nonindustrial source
  • Class Antineoplastics; Antipsoriatics; Osteoporosis therapies; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Autoimmune disorders; Renal transplant rejection; Rheumatoid arthritis; Transplant rejection; Type 1 diabetes mellitus

Most Recent Events

  • 25 Jul 2001 Discontinued-Preclinical for Transplant rejection in Sweden (Unknown route)
  • 25 Jul 2001 Discontinued-Preclinical for Rheumatoid arthritis in Sweden (Unknown route)
  • 25 Jul 2001 Discontinued-Preclinical for Type-1 diabetes mellitus in Belgium (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top